All In Biotech

Drug Trial Radar · NCT03516981

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 245 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

245

Actual

Start

Oct 1, 2018

Primary completion

Jun 13, 2025

Study completion Jun 13, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile \[GEP\] and tumor mutational burden \[TMB\]) will be randomized to receive pembrolizumab in combination with quavonlimab (MK-1308), favezelimab (MK-4280), or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either quavonlimab, favezelimab, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.

Conditions

  • Advanced Non-Small Cell Lung Cancer

Interventions

  • PembrolizumabBiological

    200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

  • FavezelimabBiological

    200 mg or 800 mg favezelimab solution for IV infusion administered Q3W

  • LenvatinibDrug

    20 mg lenvatinib capsules administered orally once daily

  • QuavonlimabDrug

    Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to approximately 80 months

Locations

81 sites in 16 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC- HAL ( Site 8001)

    Tempe, Arizona

  • University of California Davis Comprehensive Cancer Center ( Site 0137)

    Sacramento, California

  • University of California San Francisco ( Site 0111)

    San Francisco, California

  • UCLA Hematology/Oncology -Santa Monica ( Site 0108)

    Santa Monica, California

  • Yale University School of Medicine ( Site 0100)

    New Haven, Connecticut

  • Mayo Clinic Florida ( Site 0115)

    Jacksonville, Florida

  • University of Maryland ( Site 0136)

    Baltimore, Maryland

  • Mayo Clinic Rochester - St. Mary's Hospital ( Site 0117)

    Rochester, Minnesota

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0112)

    Hackensack, New Jersey

  • Memorial Sloan Kettering Cancer Center ( Site 0113)

    New York, New York

  • Weill Cornell Medical College ( Site 0138)

    New York, New York

  • Oncology Hematology Care ( Site 8005)

    Cincinnati, Ohio

  • University of Pennsylvania ( Site 0132)

    Philadelphia, Pennsylvania

  • UPMC Cancer Center/Hillman Cancer Center ( Site 0104)

    Pittsburgh, Pennsylvania

  • Texas Oncology-Memorial City ( Site 8006)

    Houston, Texas

  • Texas Oncology-Tyler ( Site 8003)

    Tyler, Texas

  • Emily Couric Clinical Cancer Center ( Site 0134)

    Charlottesville, Virginia

  • Northwest Cancer Specialists, P.C. ( Site 8000)

    Vancouver, Washington

  • University of Wisconsin- Madison Carbone Cancer Center ( Site 0130)

    Madison, Wisconsin

  • Blacktown Hospital Western Sydney Local Health District ( Site 0200)

    Blacktown, New South Wales, Australia

  • Gallipoli Medical Research Foundation ( Site 0202)

    Brisbane, Queensland, Australia

  • Fiona Stanley Hospital ( Site 0201)

    Murdoch, Western Australia, Australia

  • The Ottawa Hospital ( Site 0306)

    Ottawa, Ontario, Canada

  • Sunnybrook Health Science Centre ( Site 0304)

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 0309)

    Toronto, Ontario, Canada

  • CIUSSS du Saguenay-Lac-St-Jean ( Site 0305)

    Chicoutimi, Quebec, Canada

  • Jewish General Hospital ( Site 0307)

    Montreal, Quebec, Canada

  • CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0310)

    Montreal, Quebec, Canada

  • Prince of Wales Hospital ( Site 1801)

    Hong Kong, Hong Kong

  • Queen Mary Hospital ( Site 1800)

    Hong Kong, Hong Kong

  • St James Hospital ( Site 2200)

    Dublin, Ireland

  • Mid Western Cancer Centre ( Site 2201)

    Limerick, Ireland

  • Azienda Ospedaliera Papardo ( Site 0706)

    Messina, Italy

  • Seconda Universita degli Studi di Napoli ( Site 0704)

    Naples, Italy

  • Fondazione Policlinico Universitario A. Gemelli ( Site 0703)

    Roma, Italy

  • Azienda Ospedaliera Universitaria Senese ( Site 0705)

    Siena, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0702)

    Meldola, Emilia-Romagna, Italy

  • Istituto Clinico Humanitas Research Hospital ( Site 0700)

    Rozzano, Lombardy, Italy

  • AOU San Luigi Gonzaga di Orbassano ( Site 0707)

    Orbassano, Torino, Italy

  • AULSS21 Regione Veneto Ospedale Mater Salutis - Legnago ( Site 0701)

    Legnago, Verona, Italy

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.